At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 643 enrolled
Drug / intervention
LY2624803 +3 moredrug
Likely dose
LY2624803 1 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Study of the Safety and Efficacy of LY2624803 in Outpatients With Insomnia
In Brief
A Phase 2 clinical trial evaluating LY2624803, Placebo, and 1 other intervention for Primary Insomnia and Secondary Insomnia. Completed, enrolled 643 participants across 49 sites.
Detailed Summary
The purpose of this study is to compare an investigational drug (LY2624803) with placebo and with zolpidem in the treatment of outpatients with chronic insomnia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPrimary Insomnia, Secondary Insomnia
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2008
First PostedNov 2008
Primary CompletionFeb 2010
TodayJul 2026
First PostedNov 4, 2008
Enrollment StartOct 1, 2008
Primary CompletionFeb 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 17.7 years ago
Interventions
LY2624803drug
1 mg, oral capsule, once nightly before bedtime
LY2624803drug
3 mg, oral capsule, once nightly before bedtime
Placebodrug
matching placebo (capsule or tablet), once nightly before bedtime
zolpidemdrug
5 or 10 mg, oral tablet, once nightly before bedtime